NMS E194

Drug Profile

NMS E194

Alternative Names: NMS-E194

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Nerviano Medical Sciences
  • Class Antineoplastics; Arylsulfonates; Sulfonamides
  • Mechanism of Action EIF 2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Multiple myeloma in Italy (PO)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Multiple myeloma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top